UW Medicine Division of Allergy and Infectious Diseases
Directory >> Connie Celum, MD, MPH

Faculty

Connie Celum, MD, MPH

  • Professor of Medicine and Global Health
  • Director of the International Clinical Research Center, Global Health
  • Adjunct Professor of Epidemiology

Dr. Celum's research currently focuses on clinical trials of biomedical HIV prevention and combination HIV prevention strategies with the objective to find effective strategies to reduce HIV acquisition and transmission.

Dr. Celum's recently completed international, multi-center HIV prevention trials include genital herpes suppression for prevention of HIV acquisition among heterosexual women in Africa and men who have sex with men in the Americas (HPTN 039) and among HIV infected persons in African serodiscordant couples to reduce HIV transmission and disease progression (Partners in Prevention).

Dr. Celum is the Principal Investigator of a phase 3 randomized, placebo-controlled trial of pre-exposure antiretroviral prophylaxis, of oral tenofovir and Truvada for prevention of HIV acquisition in serodiscordant couples in Kenya and Uganda. She is a co-investigator in the NIH-funded Microbicides Trials Network. Dr. Celum is PI of a NIH grant on combination HIV prevention strategies for the heterosexual HIV epidemic in Africa. Most of her research is conducted through international collaborations, including with colleagues and sites in Peru, Kenya, and Uganda. She has many collaborators; among them, Drs. McElrath, Marrazzo, Corey, Wald, Lingappa, Baeten and Holmes.

Selected Publications

Ruark AH, Shelton JD, Halperin DT. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010 May 6;362(18):1741; author reply 1741-2. PMID: 20449879
[The following link will open in a new window. PubMed Abstract ]

Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, McIntyre J, Lingappa JR, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010 Jun 12;375(9731):2092-8. PMID: 20537376
[The following link will open in a new window. PubMed Abstract ]

Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Magaret AS, Wang RS, Kidoguchi L, Barnes L, Ridzon R, Corey L, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet. 2010 Mar 6;375(9717):824-33. PMCID: PMC2877592
[The following link will open in a new window. PubMed Abstract ]

Baeten JM, Strick LB, Lucchetti A, Whittington WLH, Sanchez J, Coombs RW, Magaret A, Wald A, Corey L, Celum C. Herpes Simplex Virus Suppressive Therapy Decreases Plasma and Genital HIV-1 Levels in HSV-2/HIV-1 Co-infected Women: A Randomized, Placebo-Controlled, Cross-Over Trial, J Infect Dis. 2008; 198: 1804-1808.
[ The following link will open in a new window. PubMed Abstract ]

Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delaney-Moretlwe S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. The Lancet. 2008; 371(9630): 2109-2119.
[ The following link will open in a new window. PubMed Abstract ]

to top